Takura is a Swedish company that commercializes advanced cell therapy research in order to accelerate the development and make groundbreaking treatments accessible and more affordable.
Contact us
Håkan Hallberg
CEO
hakan.hallberg@takura.se
Maria Rankka
EVP Business Development & Communications
maria.rankka@takura.se
Latest news
- Takura acquires Polybiocept GmbH 14 juli, 2020
- Takura joins forces with Abu Dhabi 26 september, 2019
Takura acquires Polybiocept GmbH
/0 Kommentarer/i Okategoriserade /av Maria RankkaTakura has acquired all shares in clinical stage immuno-oncology company Polybiocept GmbH (PBC). Takura was already a minority owner in the company which owns a patent portfolio for TIL (tumor infiltrating lymphocytes) therapy. Immunotherapy is one of the fastest growing segments in the pharmaceutical industry and has the potential to revolutionize cancer care. PBC has a collaboration with Krankenhaus Nordwest (KHNW) in Frankfurt where 16 patients with solid cancers have been treated with PBC’s technology under hospital exemption. The company has now started to plan for a phase I clinical trial.
Takura joins forces with Abu Dhabi
/i News /av mattiasRead more here